ACI-24 (anti-Abeta vaccine)

November 4, 2025: AC Immune SA (NASDAQ: ACIU) reported Q3 2025 results and outlined upcoming neurodegeneration pipeline catalysts following a strategic review that prioritized three Phase 2 active immunotherapies plus small-molecule programs (NLRP3, Tau, a-syn). The company reduced headcount ~30% and reported cash resources of CHF 108.5 million as of Sept. 30, 2025, projecting runway to end of Q3 2027 (excluding potential milestones).

Key upcoming milestones (expected Q4 2025 unless noted):

• ACI-7104.056 (anti-alpha-syn active immunotherapy, Parkinson’s disease): further interim Part 1 Phase 2 VacSYn results, including pharmacodynamics and biomarkers.
• ACI-24.060 (anti-Abeta active immunotherapy, Alzheimer’s): ABATE Phase 2 reaches 12-month treatment timepoint in the AD3 cohort by year-end; interim results to follow; additional results expected in H1 next year.
• ACI-19764 (small-molecule NLRP3 inhibitor): IND/CTA filing.
• Morphomer-Tau aggregation inhibitor: lead declaration and start of IND-enabling studies.
• Morphomer a-syn aggregation inhibitor: lead declaration.
• TDP-43 PET tracer (incl. ACI-19626): initial Phase 1 readout in genetic FTD.
• ACI-15916 (a-syn PET tracer): Phase 1 readout in PD.

The update also notes peer-reviewed publications, including clinical results from the completed Phase 1b/2a ACI-35.030 (JNJ-64042056/JNJ-2056; Janssen partner) in eBioMedicine.